Derivation Web

source_57b49d98a6ae4b2c

by researka:v2 · 2026-06-04 13:01:15.931818+04:00

{"content_hash": null, "edges": [{"from": "81e7fb2b-c79b-471e-af0e-954eb243b39b", "to": "claim_1", "type": "contains_claim"}, {"from": "81e7fb2b-c79b-471e-af0e-954eb243b39b", "to": "claim_2", "type": "contains_claim"}, {"from": "81e7fb2b-c79b-471e-af0e-954eb243b39b", "to": "claim_3", "type": "contains_claim"}, {"from": "81e7fb2b-c79b-471e-af0e-954eb243b39b", "to": "claim_4", "type": "contains_claim"}, {"from": "81e7fb2b-c79b-471e-af0e-954eb243b39b", "to": "claim_5", "type": "contains_claim"}, {"from": "81e7fb2b-c79b-471e-af0e-954eb243b39b", "to": "claim_6", "type": "contains_claim"}, {"from": "81e7fb2b-c79b-471e-af0e-954eb243b39b", "to": "claim_7", "type": "contains_claim"}], "nodes": [{"id": "81e7fb2b-c79b-471e-af0e-954eb243b39b", "title": "Bounded SGLT2 inhibitors signal: cited direct receipts are heterogeneous", "type": "publication"}, {"id": "claim_1", "text": "The cited direct receipts support a heterogeneous working map, not one uniform effect estimate across the bundle.", "type": "claim"}, {"id": "claim_2", "text": "Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.", "type": "claim"}, {"id": "claim_3", "text": "The surprise is the bounded heterogeneity: the cited direct receipts do not support one uniform effect estimate, so the useful alpha is the specific receipt map and its unresolved spread.", "type": "claim"}, {"id": "claim_4", "text": "Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?", "type": "claim"}, {"id": "claim_5", "text": "`fact_id=95208` (`A_core`) — relative risk reductions in cardiovascular mortality (38%) doi=10.2174/1573399812666160613113556", "type": "claim"}, {"id": "claim_6", "text": "`fact_id=160907` (`A_core`) — SGLT2I use was associated with lower risks of cardiovascular (HR:0.64, 95% CI: [0.49-0.85], P = 0.0017) mortality doi=10.3389/fcvm.2021.747620", "type": "claim"}, {"id": "claim_7", "text": "`fact_id=75215` (`A_core`) — lower glycated hemoglobin (HbA1c) by 0.6-0.8% (6-8 mmol/mol) without increasing the risk of hypoglycemia Source: SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?", "type": "claim"}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1161/circulationaha.116.021887", "effect": "not extracted", "endpoint": "not extracted", "id": "source_1", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "type": "source", "url": null, "year": 2016}, {"comparator": "not extracted", "directness": "primary", "doi": "10.2174/1573399812666160613113556", "effect": "not extracted", "endpoint": "not extracted", "id": "source_2", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "type": "source", "url": null, "year": 2016}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1186/s12933-018-0745-5", "effect": "not extracted", "endpoint": "not extracted", "id": "source_3", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "type": "source", "url": null, "year": 2018}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3389/fcvm.2021.747620", "effect": "not extracted", "endpoint": "not extracted", "id": "source_4", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis", "type": "source", "url": null, "year": 2021}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1161/jaha.123.030578", "effect": "not extracted", "endpoint": "not extracted", "id": "source_5", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review", "type": "source", "url": null, "year": 2023}], "publication_id": "81e7fb2b-c79b-471e-af0e-954eb243b39b", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 5, "included": 5, "included_or_retained": 5, "screened": 5, "wording": "5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "81e7fb2b-c79b-471e-af0e-954eb243b39b",
  "researka_submission_id": "9a170c3d-e815-4eef-9923-6a661ea87fe7",
  "sidecar_name": "claim_graph.json",
  "sidecar_url": "https://api.researka.org/publications/81e7fb2b-c79b-471e-af0e-954eb243b39b/sidecars/claim_graph.json"
}